Myelodysplastic syndrome with excess blasts
MONDO:0019454A myelodysplastic syndrome characterized by the presence of 5-19% myeloblasts in the bone marrow or 2-19% blasts in the peripheral blood. It includes two categories: myelodysplastic syndrome with excess blasts-1 and myelodysplastic syndrome with excess blasts-2.
Also known as: MDS-EB, RAEB, myelodysplastic syndrome with Excess blasts, refractory Anaemia with Excess blasts, refractory Anaemia with an Excess of blasts, refractory Anemia with Excess blasts, refractory Anemia with an Excess of blasts
1929 clinical trials for this condition and its sub-types, 72 tagged with Myelodysplastic syndrome with excess blasts itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myelodysplastic syndrome with excess blasts
-
Which Pre-Transplant chemo works best for MDS/AML? new trial aims to find out
Disease control Stopped earlyThis phase II trial tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant in adults with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free s…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control Stopped earlyThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase 1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control Stopped earlyThis early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC